Benitec Biopharma at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
Benitec Biopharma brings 2 presentations to ESGCT 2026 in Hamburg. Its presence centres on its gene therapy for oculopharyngeal muscular dystrophy. The data cover durable responses out to two years in patients with swallowing difficulty given the low dose, plus interim results from a higher dose.
| Organization | ESGCT 2026 Attendance |
|---|---|
Benitec Biopharma Hayward, California | |
Develops gene therapies that pair RNA interference with gene replacement, led by BB-301 for oculopharyngeal muscular dystrophy. | Poster Wed Oct 28 1:30pm–3:30pm Durable Responses to Low-Dose Investigational Gene Therapy BB-301 in Patients with Oculopharyngeal Muscular Dystrophy (OPMD) with Dysphagia and Summary of Interim Clinical Results for High-Dose BB-301 Poster Thu Oct 29 2:00pm–4:00pm Durable responses to low-dose investigational gene therapy BB-301 in patients with Oculopharyngeal Muscular Dystrophy (OPMD) with dysphagia at 12-months and 24-months post-treatment and improved depth of response to high-dose BB-301 |
Instantly find 20 buyers from Benitec Biopharma
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction